MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 214 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.87 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $7,954,254 | +163.1% | 34,434 | +175.9% | 0.31% | +170.4% |
| Q1 2023 | $3,023,647 | +132.8% | 12,481 | -6.4% | 0.12% | +173.8% |
| Q2 2021 | $1,299,000 | -16.7% | 13,340 | 0.0% | 0.04% | -22.2% |
| Q1 2021 | $1,560,000 | +5.2% | 13,340 | 0.0% | 0.05% | +3.8% |
| Q4 2020 | $1,483,000 | -6.4% | 13,340 | 0.0% | 0.05% | -11.9% |
| Q3 2020 | $1,584,000 | +4.8% | 13,340 | 0.0% | 0.06% | +1.7% |
| Q2 2020 | $1,511,000 | +69.6% | 13,340 | 0.0% | 0.06% | +45.0% |
| Q1 2020 | $891,000 | -26.7% | 13,340 | 0.0% | 0.04% | -13.0% |
| Q4 2019 | $1,215,000 | +5.7% | 13,340 | 0.0% | 0.05% | -8.0% |
| Q3 2019 | $1,150,000 | -17.7% | 13,340 | 0.0% | 0.05% | -12.3% |
| Q2 2019 | $1,398,000 | -16.3% | 13,340 | 0.0% | 0.06% | -16.2% |
| Q1 2019 | $1,671,000 | +122.2% | 13,340 | +100.0% | 0.07% | +112.5% |
| Q4 2018 | $752,000 | -47.3% | 6,670 | 0.0% | 0.03% | -38.5% |
| Q3 2018 | $1,428,000 | – | 6,670 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tao Capital Management LP | 77,657 | $5,047,000 | 3.31% |
| L1 Capital Pty Ltd | 161,163 | $10,474,000 | 2.05% |
| Avoro Capital Advisors LLC | 1,535,000 | $99,760,000 | 1.84% |
| Affinity Asset Advisors, LLC | 100,000 | $6,499,000 | 1.81% |
| GREAT POINT PARTNERS LLC | 95,500 | $6,207,000 | 1.50% |
| ARMISTICE CAPITAL, LLC | 1,236,000 | $80,328,000 | 1.39% |
| Affinity Asset Advisors, LLC | 75,000 | $4,874,000 | 1.36% |
| MPM BioImpact LLC | 44,747 | $2,908,000 | 0.69% |
| Baker Brothers Advisors | 1,499,213 | $97,434,000 | 0.64% |
| Perceptive Advisors | 331,023 | $21,513,000 | 0.62% |